Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1921-1930 of 2905 for cancer

Edit search filters
  1. Study Of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily And In Combination With Dabrafenib Twice Daily And Trametinib Once Daily In Combination Therapy In Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

    Rochester, MN

  2. Outcomes After Secondary Cytoreductive Surgery With Or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed By Systemic Combination Chemotherapy For Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

    Rochester, MN

  3. A Phase 2, Multicenter, Study Of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib In Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) And BDX004 Positive Label

    Rochester, MN

  4. A Study Evaluating Safety And Efficacy Of The Addition Of ABT-888 Plus Carboplatin Versus The Addition Of Carboplatin To Standard Chemotherapy Versus Standard Chemotherapy In Subjects With Early Stage Triple Negative Breast Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  5. A Study To Evaluate The Safety And Effectiveness Of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant As Treatment For Locally Advanced (Inoperable) Or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer

    Jacksonville, FL, Rochester, MN

  6. A Study Of Pembrolizumab (MK-3475) Versus Placebo In Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy In The Treatment Of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

    Rochester, MN

  7. Study To Assess Adverse Events And Change In Disease Activity In Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer In Combination With IV Fluorouracil, Folinic Acid, And Bevacizumab

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. A Study Of Amivantamab In Combination With Lazertinib, Or Amivantamab In Combination With Platinum-Based Chemotherapy, For Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Jacksonville, FL, Rochester, MN

  9. Efficacy And Safety Of REC-2282 In Participants With Progressive NF2 Mutated Meningiomas (POPLAR-NF2)

    Rochester, MN

  10. A Study To Assess The Effectiveness And Safety Of UGN-102 As A Primary Chemoablation Agent In Patients With Low Grade Non-Muscle-Invasive Bladder Cancer (LG NMIBC) At Intermediate Risk Of Recurrence

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer